Classes of HIV/AIDS Antiretroviral Drugs
The antiretroviral medications used to treat HIV/AIDS currently are organized into
five major drug classes.
Reverse Transcriptase (RT) Inhibitors interfere with the critical
step during the HIV life cycle known as reverse transcription. During this step,
the HIV enzyme RT converts HIV RNA to HIV DNA. There are two main types of RT inhibitors.
- Nucleoside/nucleotide RT inhibitors are faulty DNA building blocks. When these faulty
pieces are incorporated into the HIV DNA (during the process when HIV RNA is converted
to HIV DNA), the DNA chain cannot be completed, thereby blocking HIV from replicating
in a cell.
- Non-nucleoside RT inhibitors bind to RT, interfering with its ability to convert
the HIV RNA into HIV DNA.
Protease Inhibitors interfere with the protease enzyme that HIV
uses to produce infectious viral particles.
Fusion/Entry Inhibitors interfere with the virus' ability to fuse
with the cellular membrane, thereby blocking entry into the host cell.
Integrase Inhibitors block integrase, the enzyme HIV uses to integrate
genetic material of the virus into its target host cell.
Multidrug Combination Products combine drugs from more than one
class into a single product. To combat virus strains from becoming resistant to
specific antiretroviral drugs, healthcare providers recommend that people infected
with HIV take a combination of antiretroviral drugs known as highly active antiretroviral
therapy (HAART). Developed by NIAID-supported researchers, the HAART strategy combines
drugs from at least two different antiretroviral drug classes.
Another HIV/AIDS drug class known as maturation inhibitors is still in development.
If successful, they could potentially prevent HIV from properly assembling
and maturing. For example, these treatments could block HIV from forming a protective
outer coat or from emerging from human cells.
Information published courtesy of NIAID
This article was last modified in: 06/18/2012